1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Obese Non Diabetic: new trials by email Literature Review of Obese Non Diabetic trials Research Report on Obese Non Diabetic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician - Obese Diabetics, Obese Non Diabetic | Phase 3 | Completed | Zagazig University | 159 | 2025-10-18 | 2026-09-15 |
Diabetes Mellitus, Type 2 (1) · Obesity (1)
Body Weight (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Overweight (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Injections, Subcutaneous (1) · Obesity Management (1) · Tirzepatide (1) · dulaglutide (1) · semaglutide (1)
Saudi Arabia (1)